期刊
CANCER LETTERS
卷 511, 期 -, 页码 26-35出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.04.017
关键词
TNFAIP3; Lymphoma; Hepatocellular carcinoma; Colorectal carcinoma; Breast cancer
类别
资金
- National Nature Science Foundation of China [81672806, 81972685]
- Key Research and Development Program of Shandong Province [2017GSF218066]
This review highlights the varying roles of A20 in different cancer types, showcasing its anti-tumor effects in colorectal carcinomas and hepatocellular carcinomas, while acting as an oncogene in breast cancers, gastric cancers, and melanomas. The context-dependent nature of A20 in glioma therapy is also discussed.
A20 is a prototypical anti-inflammatory molecule that is linked to multiple human diseases, including cancers. The role of A20 as a tumor suppressor was first discovered in B cell lymphomas. Subsequent studies revealed the dual roles of A20 in solid cancers. This review focuses on the roles of A20 in different cancer types to demonstrate that the effects of A20 are cancer type-dependent. A20 plays antitumor roles in colorectal carcinomas and hepatocellular carcinomas, whereas A20 acts as an oncogene in breast cancers, gastric cancers and melanomas. Moreover, the roles of A20 in the setting of glioma therapy are context-dependent. The action mechanisms of A20 in different types of cancer are summarized. Additionally, the role of A20 in antitumor immunity is discussed. Furthermore, some open questions in this rapidly advancing field are proposed. Exploration of the actions and molecular mechanisms of A20 in cancer paves the way for the application of A20-targeting approaches in future cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据